IDEAYA BIOSCIENCES Reports Fourth Quarter FY2022 Earnings Results on March 7 2023.

March 19, 2023

Earnings Overview

IDEAYA BIOSCIENCES ($BER:30J) reported their FY2022 fourth quarter earnings results on March 7 2023, showing a 32.9% decrease in total revenue from the same quarter the previous fiscal year, ending at USD -24.2 million. However, net income increased by 35.8%, finishing at USD 4.0 million.

Stock Price

On Tuesday, IDEAYA BIOSCIENCES released its fourth quarter earnings results for FY2022, with the stock opening up at €15.8 and closing at €17.0, a 7.6% increase from the previous day’s closing price. Overall, the company’s results demonstrate strong performance and growth in their operations, with the potential for even more development and revenue growth in the coming year. This positive performance bodes well for investors and shareholders alike, as IDEAYA BIOSCIENCES continues to focus on creating innovative products and solutions to meet customer needs. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Ideaya Biosciences. More…

    Total Revenues Net Income Net Margin
    50.93 -60.81 -115.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Ideaya Biosciences. More…

    Operations Investing Financing
    -87.17 -33.4 97.17
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Ideaya Biosciences. More…

    Total Assets Total Liabilities Book Value Per Share
    387.97 38.51 7.25
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Ideaya Biosciences are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -177.9% -10.9% -10.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have conducted an analysis of IDEAYA BIOSCIENCES‘s financials. Our Risk Rating has identified this company as a medium risk investment in terms of financial and business aspects. We discovered two risk warnings in their balance sheet and cashflow statement. To find out more information about this investment, register on Our platform will provide you with an in depth analysis of IDEAYA BIOSCIENCES’s financials, enabling you to make a more informed decision. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Summary

    IDEAYA BIOSCIENCES recently announced their fourth quarter FY2022 results, showing a 32.9% decrease in total revenue from last year and a 35.8% increase in net income. This news caused their stock price to rise on the same day. Investors may be encouraged by the company’s overall financial performance and outlook, as a decrease in revenue was offset by an increase in net income. However, a thorough analysis of the company’s financials should be conducted before investing.

    Recent Posts

    Leave a Comment